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SUMMARY: Aneurysmal subarachnoid hemorrhage is associated with high morbidity and
mortality, with delayed neurologic deficits from delayed cerebral ischemia contributing to a large
portion of the adverse outcomes in this patient population. There is currently no consensus
reference standard for establishing the diagnosis of delayed cerebral ischemia either in the
research or clinical settings, ultimately limiting strategies for preventing delayed infarction and
permanent neurologic deficits. There are currently both clinical and imaging-based criteria for the
diagnosis of delayed neurologic deficits and vasospasm, respectively, however, neither clinical nor
angiographic assessment alone has been shown to identify patients who develop adverse outcomes
from delayed infarction. Thus, the purpose of this work is to propose a 3-tiered combined imaging
and clinical reference standard based on evidence from the literature to standardize the diagnosis
of delayed cerebral ischemia, both to allow consistency across research studies and to ultimately
improve outcomes in the clinical setting.
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A neurysmal subarachnoid hemorrhage (aSAH) is associated with high morbidity and
mortality.1,2 The first 2 weeks following aSAH are critical in the management of these
patients because they are prone to develop several life-threatening complications, including
delayed neurologic deficits,3 which often arise from delayed cerebral ischemia (DCI), a
major contributor to the adverse outcomes in this population.3–5 Delayed cerebral ischemia
manifests in approximately 30% of patients with aSAH and typically occurs between days 4
and 9 after the initial hemorrhage, though it can range from 3 to 14 days.
There remains a lack of standard criteria for defining DCI in the clinical setting,3,6,7 with a
recent literature review describing at least 8 terms to define the concept of DCI in aSAH.6
Debate over the role of clinical and imaging assessments in defining DCI has occurred for
both clinical and research purposes.3,6,8–10 For example, although the terms “DCI” and
“vasospasm” have been used interchangeably, attempts have been made to distinguish DCI
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from vasospasm, with the former often determined clinically, and the latter,
radiographically,6 because not all patients with clinical neurologic deficits have
angiographic vasospasm and not all patients with angiographic vasospasm have neurologic
deficits that correspond to the arterial territory of vasospasm.11,12 Additionally, while severe
vasospasm may cause decreased cerebral perfusion, a substantial percentage of patients
develop infarction without evidence of vasospasm, suggesting that DCI should be defined as
a pathologic process, of which vasospasm may represent a contributing factor.12,13
Thus, the aim of this article is to propose an evidence-based reference standard for DCI that
incorporates both clinical assessments of neurologic deterioration and imaging assessments
of vasospasm, perfusion deficits, and infarction to provide a consistent, uniform standard
across a wide range of clinical and research applications. The classification of levels of
evidence supporting this reference standard is based on the Levels of Evidence criteria
proposed by the Oxford Centre of Evidence Based Medicine (www.cebm.net).14 Two
independent reviewers assessed levels of evidence for each tier, and in the case of
discordance, evidence level assignments were made by consensus.

DESCRIPTION OF THE COMBINED CLINICAL AND IMAGING REFERENCE
NIH-PA Author Manuscript

STANDARD
(Algorithm displayed in Fig 1)
Primary Level: Outcome-Based Criteria

NIH-PA Author Manuscript

Summary—The primary level classifies patients as having DCI if a new infarction on
imaging or new permanent neurologic deficit develops. A new infarction on imaging is
determined on CT or MR imaging within 6 weeks after aSAH ictus that was not present on
imaging up to 48 hours after aneurysm occlusion and was not attributable to other causes
such as surgical clipping, endovascular treatment, ventricular catheter placement,
intraparenchymal hematoma, or cerebral herniation. A new permanent neurologic deficit is
determined on clinical examination as a new neurologic deficit distinct from the baseline
examination performed immediately after aneurysm rupture or aneurysm occlusion and not
attributable to other causes. Baseline neurologic examination must be considered after full
cardiorespiratory, hemodynamic, and metabolic resuscitation as well as treatment of other
factors such as seizures and hydrocephalus. Patients who do not meet either criterion are
referred to the secondary level, as described in a subsequent section.
Evidence: Level 1A evidence exists to support these proposed outcomes-based criteria for
determining DCI.
An ideal reference standard should reliably identify patients with a high risk of poor
outcomes who may benefit from intervention. In large prospective cohort studies, the
greatest predictors of severe disability or death at 3 months were a new focal neurologic
deficit, a new infarction on follow-up imaging, or both.6,15,16 Additionally, a large
systematic review and meta-analysis of all randomized placebo-controlled trials evaluating
the efficacy of protective strategies in aSAH concluded that a reduced incidence of cerebral
infarction is significantly associated with improved functional outcome.17 In fact, new
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cerebral infarction alone was as strongly correlated with poor 3-month functional outcome
as the combination of a new neurologic deficit and corresponding ischemic changes on
follow-up neuroimaging.6 Furthermore, cerebral infarction on noncontrast CT was the
primary outcome measure in the early trials of nimodipine, an agent with strong evidence for
neuroprotection of DCI.18
While angiographic vasospasm has traditionally been the primary focus of interventions and
prediction of outcomes, the lack of evidence demonstrating improved outcomes with
vasospasm prevention13,19 has led to incorporating this criterion combined with clinical
correlation in the secondary level below.
Secondary Level: Correlation of Clinical and Vascular Imaging Criteria
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Summary—The secondary level classifies patients as having DCI if both clinical
deterioration and angiographic vasospasm occur. Clinical deterioration is determined by
bedside examination and comprises the development of a new neurologic deficit (such as
hemiparesis, hemiplegia, aphasia, depressed consciousness, and so forth), a decrease of at
least 2 points on the Glasgow Coma Scale, or a decrease of at least 1 point in the motor
score, lasting >1 hour at any point after aneurysm occlusion and not attributable to other
causes. Vascular imaging for the evaluation of vasospasm includes imaging modalities, such
as transcranial Doppler sonography, CTA, MRA, and DSA. Patients with neurologic
deterioration and 1 imaging test supporting a diagnosis of vasospasm are classified as having
DCI. On the other hand, patients without neurologic deterioration and 1 imaging test without
findings of vasospasm are classified as not having DCI. However, patients with either
positive clinical or imaging findings that do not correlate with each other are referred to the
tertiary level, as described in a subsequent section.
Evidence: Level 1B evidence exists to support using clinical and vascular imaging data for
determining DCI.
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Evaluation of patients for DCI at the secondary level is most valuable in the clinical setting
at the point of care when treatment decisions are made. The primary goal of treatment is to
prevent cerebral infarction and permanent neurologic deficits. Thus, traditionally, imaging
assessment of vasospasm has been used as a surrogate marker to assist in the diagnosis of
DCI, especially given that neurologic deterioration is poorly evaluated in sedated or
obtunded patients. Angiographic vasospasm, seen on DSA or CTA, is perhaps the most
commonly used surrogate imaging marker in this patient population. Vasospasm has been
shown to be strongly associated with DCI, cerebral infarction, poor outcome, and increased
mortality within several retrospective and prospective cohort studies, including a post hoc
analysis of data from the CONSCIOUS (Clazosentan to Overcome Neurological Ischemia
and Infarct Occurring after Subarachnoid Hemorrhage)- 1 trial.11,20–23 However, an analysis
of data from 2 systematic reviews and a post hoc analysis did not demonstrate an
improvement in outcome with a reduction in angiographic vasospasm.19 Evidence from both
prospective and retrospective cohort studies suggests that patients with angiographic
vasospasm and correlated symptoms have worse hospital complications and subsequent
disability compared with angiographic vasospasm alone.9,16 However, there is less evidence
to demonstrate the prognostic importance of angiographic vasospasm correlated with
AJNR Am J Neuroradiol. Author manuscript; available in PMC 2015 December 01.
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symptoms, thus placing this criterion at the secondary level. Although relatively inferior in
terms of sensitivity and specificity, transcranial Doppler sonography evaluations of the
intracranial vessels can also be performed at bedside to identify arterial narrowing in
patients who may be too unstable for more advanced angiographic techniques such as CTA,
MRA, or DSA.24,25
Tertiary Level: Correlation of Physiologic Data with Clinical or Imaging Criteria
Summary—The tertiary level classifies patients as having DCI if physiologic data
correlates with either clinical deterioration or vasospasm. Patients with either clinical
deterioration or vasospasm alone may undergo additional physiologic assessment of cerebral
hemodynamics, either in the form of imaging such as CTP and MR perfusion (MRP) or
neuromonitoring devices such as cerebral blood flow, oxygen tension monitoring, and
cerebral microdialysis. Patients with findings suggestive of regional cerebral hypoperfusion
or hypoxia that correlate with either clinical deterioration or vasospasm are classified as
having DCI. Patients with clinical deterioration or vasospasm but normal physiologic data
do not have sufficient evidence to be classified as having DCI.

NIH-PA Author Manuscript

Evidence: Levels of evidence to support using physiologic data for determining DCI range
from 2A to 3B, depending on the technique.

NIH-PA Author Manuscript

While there is at least moderate evidence supporting the importance of symptomatic
vasospasm in DCI at the secondary level, the importance of isolated image-based diagnoses
of vasospasm in the absence of clinical findings is somewhat controversial, especially in the
absence of infarction. However, a subset of patients with asymptomatic vasospasm will
develop asymptomatic ischemia and subsequent infarction. A large prospective cohort
identified asymptomatic infarction in approximately 20% of patients with aSAH, and
furthermore, these patients had a higher frequency of death and moderate-to-severe
disability at 3 months relative to patients with symptomatic infarction.26 Thus, there may be
a subset of patients with apparently asymptomatic vasospasm who are at high risk of
eventually developing clinical evidence of DCI, especially those who are comatose or have a
ventriculostomy catheter, small-volume aSAH, or ischemia in noneloquent brain26,27—all
representing complicating factors that are not infrequently encountered in the intensive care
setting. Identifying this high-risk subset of patients with asymptomatic vasospasm may
prompt measures to implement therapies to prevent the eventual development of DCI.
Conversely, the identification of patients with DCI and clinical deterioration in the absence
of vasospasm poses a different important diagnostic challenge. While neurologic
deterioration is likely multifactorial in these patients, a subset will go on to develop
infarction without vasospasm. A retrospective study of infarction patterns in patients with
aSAH found that approximately 17% of patients developed infarcts without imaging
evidence of vasospasm, and even in patients with imaging positive for vasospasm, infarcts
also developed in areas away from the vasospastic territories.28 Thus, this level in the
algorithm would attempt to identify ischemia in patients with asymptomatic vasospasm or
neurologic deterioration without evidence of large-vessel vasospasm.
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Perfusion imaging such as CTP and MRP or less common modalities such as xenon-CT
provide physiologic imaging assessments of cerebral hypoperfusion and ischemia that could
identify patients at risk for infarction. In a retrospective cohort of 96 patients with aSAH,
new CTP deficits seen as prolonged MTT and reduced CBF were significantly associated
with subsequent infarction and permanent neurologic deficits.29 A smaller prospective study
evaluating the test characteristics of CTP, CTA, and noncontrast CT obtained at baseline and
after the onset of clinical deterioration determined that CTP had the best test performance
for the subsequent diagnosis of DCI at discharge.30 Subsequently, systematic reviews
evaluating CTP in aSAH within the broader context of diagnosing vasospasm and DCI
found that relative CBF and MTT values correlated highly with subsequent DCI.25,31 Thus,
there is level 2A evidence to support the role of CTP in the diagnosis of DCI.

NIH-PA Author Manuscript

Evidence to support the use of other imaging modalities to evaluate DCI is more limited.
There are limited data evaluating the role of MRP in DCI; however, several small
prospective cohort studies demonstrated that CTP, particularly CBF, correlates with MRPderived values in the same patients within a close time interval, suggesting that MR imaging
could also be used in this setting in case CTP is not performed.32,33 The data for the use of
xenon-CT in DCI are even more limited; however, a small prospective cohort study in
patients with poor-grade aSAH found that CBF reduction on xenon-CT was only moderately
predictive of infarction in these patients and that not all reductions in CBF by this technique
resulted in infarction.34 Thus, there is at best level 2B and 3B evidence for MRP and xenonCT, respectively, for the diagnosis of ischemia in patients with aSAH. However, these
imaging modalities are challenging to perform in this patient population due to scanner
accessibility and patient contraindications.

NIH-PA Author Manuscript

Not all patients with aSAH undergo imaging to assess ischemia, particularly those who are
unstable or have poor-grade conditions. Thus, noninvasive and invasive bedside monitoring
devices such as cerebral microdialysis, brain tissue oxygenation monitoring (eg, the Licox
system, Integra LifeSciences, Plainsboro, New Jersey), and other similar devices have been
used to stratify patients at risk of ischemia. A systemic review evaluating the use of
microdialysis in the assessment of cerebral ischemia in patients with aSAH found that while
the use of the technology is increasing, there is substantial study heterogeneity, thereby
limiting the evidence to support its utility.35 Nonetheless, a small prospective cohort of 44
patients found that a 2-fold increase in ischemia- related metabolites from baseline at the
time of acute neurologic deterioration was significantly associated with subsequent
infarction and permanent neurologic deficits.36 Data for cerebral tissue oxygen monitoring
are more limited, particularly in patients with aSAH. Several small prospective cohort
studies demonstrated the potential utility of detecting hypoxia in aSAH by using tissue
oxygenation monitoring.37–39 Thus, there is level 3A evidence in support of cerebral
microdialysis and level 3B evidence to support cerebral oxygen monitoring in patients with
aSAH.
Strengths and Limitations of Each Level
Primary Level—The main strength of the primary level is its strong evidence using
outcome-based criteria supported by systematic reviews and large observational cohort
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studies.3,15,17,19 Thus, the primary level captures patients with the highest mortality and
morbidity associated with DCI. Most important, this level emphasizes specificity over
sensitivity to accurately identify patients with DCI for treatment decisions. Additionally,
patients with DCI who do not develop infarction or neurologic deficits cannot be
misclassified at this level because these patients advance to the secondary level for further
evaluation. Another strength at this level is the reproducibility in assessing patients with
these well defined outcome measures that are less prone to inter observer variability.
The main limitation at the primary level is the reduced applicability in guiding treatment
decisions. In clinical practice, the goal of managing patients with aSAH is to avoid these
devastating outcomes of infarction and functional disability. At this level, patients are
classified as having DCI according to these criteria, thus limiting improvement in patient
outcomes with treatment.

NIH-PA Author Manuscript

Secondary Level—The main strength of the secondary level is the combination of new
neurologic deficits with imaging findings suggestive of angiographic vasospasm that have
been shown to correlate with functionally relevant outcomes.9 Because these criteria can, in
some cases, be evaluated before development of infarction and functional disability (ie, at a
stage in which impending DCI is still preventable), classification of patients with DCI at this
level should theoretically provide maximal benefit from treatment. The combination of both
new neurologic deficits and evidence of angiographic vasospasm improves the specificity
for identifying patients with DCI, given that neurologic assessment in patients with aSAH
can be challenging and angiographic vasospasm does not necessarily correlate with DCI.
A limitation of the secondary level is that patients without new neurologic deficits and
without angiographic vasospasm can be misclassified as having no DCI. Comatose or
heavily sedated patients have limited clinical assessment and may have suboptimal imaging,
resulting in false-negatives for DCI. Although the agreement of clinical and imaging
findings improves the specificity for identifying patients with DCI for treatment, the
sensitivity may not be optimized at this level for a subset of patients. The probability of
correlation is dependent on the quality of each respective evaluation, and both the clinical
and imaging assessments at this level are subject to inter observer variability.10,40,41

NIH-PA Author Manuscript

Tertiary Level—The main strength of the tertiary level is improving the sensitivity of the
DCI diagnosis by further evaluating discordant clinical and imaging findings from the
secondary level, such as in patients with asymptomatic vasospasm or neurologic decline
without angiographic vasospasm. Most important, this level allows further evaluation of
comatose patients with suboptimal clinical assessments who have angiographic vasospasm
as well as symptomatic patients who have suboptimal imaging. These patients often have
worse outcomes in comparison with patients with symptomatic DCI, possibly related to
delayed treatment. 26 At this level, all patients undergo physiologic assessment of cerebral
perfusion and hypoxia to correlate with either clinical or imaging findings suggesting DCI.
Thus, this level will include patients who may have been excluded from the diagnosis due to
lack of sufficient evidence at the other 2 levels.
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A potential limitation of the tertiary level is that the breadth of modalities used to assess
ischemia—ranging from noninvasive imaging to invasive tissue monitoring—has variable
strength of evidence to support their use. From an imaging standpoint, CTP has the strongest
evidence to support its use in diagnosing DCI; clinically, cerebral microdialysis has some
evidence to support its use despite inconclusive results from a systematic review of the
literature. There is limited evidence to support the use of the remaining modalities in
diagnosing DCI in patients with aSAH.
Future Directions

NIH-PA Author Manuscript

While there is no perfect reference standard for this complex disease process, this
multitiered algorithm attempts to capture the complexity of clinical and imaging findings in
DCI according to evidence-based criteria. Specificity is emphasized in this multitiered
reference standard with respect to evidence-based clinically relevant outcomes at the
primary level, which are particularly valuable in the research setting to potentially improve
translation of research findings into clinical practice. Most important, this reference standard
approach also incorporates levels of evidence with greater sensitivity for use in clinical
settings. The model is heavily weighted toward criteria with supportive statistical evidence
and, through a multitiered algorithm, aims to limit the heterogeneity and controversy in
defining DCI for research and, potentially, clinical application, combining both imaging and
clinical assessments in the determination of DCI. The future direction for validation of this
proposed reference standard through prospective studies may help to move forward both
clinical care and research in this field.
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aSAH

aneurysmal subarachnoid hemorrhage

DCI

delayed cerebral ischemia

MRP

MR perfusion
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Fig 1.
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Proposed multitiered reference standard in DCI. Three-tiered DCI reference standard
algorithm, ordered from top to bottom. Asterisk indicates neuromonitoring devices such as
cerebral microdialysis and oximetry. Double asterisks indicate whether the reference
standard is used for clinical assessment and treatment decisions based on the risk/benefit
ratio for treatment. If there is low risk, treatment for DCI is recommended. If there is high
risk, the patient should re-enter the algorithm.
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